Photo by nci from unsplash
e22118Background: Regorafenib is an oral small molecule inhibitor of multiple tyrosine kinases, including VEGFR, KIT, RET, RAF1, BRAF as well as PDGFR and FGFR, and is proven to be beneficial… Click to show full abstract
e22118Background: Regorafenib is an oral small molecule inhibitor of multiple tyrosine kinases, including VEGFR, KIT, RET, RAF1, BRAF as well as PDGFR and FGFR, and is proven to be beneficial in di...
Keywords:
toxicities patients;
patients cancer;
gastrointestinal hepatic;
hepatic toxicities;
risk gastrointestinal;
cancer treated
Journal Title: Journal of Clinical Oncology
Year Published: 2018
Link to full text (if available)
Share on Social Media: Sign Up to like & get
recommendations!
Journal Title: Journal of Clinical Oncology
Year Published: 2018
Link to full text (if available)
Share on Social Media: Sign Up to like & get
recommendations!